Cost-effectiveness of Statin Use Guidelines-Reply
JAMA Cardiol
.
2021 Mar 1;6(3):364.
doi: 10.1001/jamacardio.2020.6130.
Authors
Ankur Pandya
1
2
,
Jinyi Zhu
2
,
Aferdita Spahillari
3
Affiliations
1
Department of Health Policy and Management, Harvard T. H. Chan School of Public Health, Boston, Massachusetts.
2
Center for Health Decision Science, Harvard T. H. Chan School of Public Health, Boston, Massachusetts.
3
Division of Cardiology, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.
PMID:
33325987
DOI:
10.1001/jamacardio.2020.6130
No abstract available
Publication types
Letter
Comment
MeSH terms
Cholesterol, LDL
Cost-Benefit Analysis
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors* / therapeutic use
Quality-Adjusted Life Years
Substances
Cholesterol, LDL
Hydroxymethylglutaryl-CoA Reductase Inhibitors